Renal osteodystrophy caused by chronic renal failure and bone metabolism. Referred to as renal osteodystrophy. Performance for disorders of calcium and phosphorus metabolism, acid-base imbalance, skeletal deformities and may cause secondary hyperparathyroidism. Bone showed osteoporosis, osteomalacia, osteitis fibrosa, bone sclerosis and metastatic calcification young. May cause growth retardation. Then, suffering from renal osteodystrophy in patients with diet care should pay attention to what?
1, renal osteodystrophy is an important complication in patients with chronic kidney disease and dialysis, treatment should be emphasized in the early prevention and early kidney damage can be used in small doses of 1,25- (OH) 2D3 and oral calcium, to prevent severe hyperparathyroidism and parathyroid hyperplasia; and comprehensive treatment measures according to the reasonable type of bone disease.
2, during the application of active vitamin D treatment should be closely monitored, blood calcium, blood phosphorus and IPTH levels, avoid hypercalcemia, hyperphosphatemia, metastatic calcification and adynamic bone disease.
Renal osteodystrophy, diet, health care
In the past ten years, vitamin D active derivatives, has opened up a new path for our treatment of renal osteodystrophy. Active derivatives of vitamin D 1 alpha (OH) D3,25 (OH) 2 D3,1,25 (OH) 2 D3, double hydrogen tachysterol (DHT), 22- oxygen - cholecalciferol (OCT), especially 1,25 (OH) 2 D significantly increased the serum calcium concentration, inhibition of parathyroid hormone gene transcription, thereby inhibiting the light, moderate primary hyperparathyroidism, correct bone tissue resistance to PTH, to a great extent improve bone disease.
But at present the use of clinical is still limited as follows: 1. In the treatment of hypercalcemia: often after a few weeks or 3 months after the occurrence of high PTH hyperlipidemia; the hard to correct: This is due to chronic renal failure patients on parathyroid calcium feedback inhibition caused by decreased sensitivity; for severe osteitis fibrosa or symptomatic secondary hyperparathyroidism in patients with poor effect; the transfer of ossification and renal function may decline. The use of 1,25 (OH) 2 D3 should pay attention to detection of calcium phosphorus product.